Founded in 2020, Inceptor Bio is a biotechnology company developing multiple next-generation cell and gene therapy platforms to deliver cures for underserved and difficult-to-treat cancers. By partnering with universities, medical centers, and industry leaders, Inceptor Bio advances cell and gene therapy programs from discovery-phase technologies into Phase I and II clinical assets. An experienced management team, Scientific Advisory Board, Directors and strategic advisors offer industry-leading expertise to partnerships. Inceptor Bio is investing in an Advanced Manufacturing Platform (AMP+) to provide fit-for-purpose, capital efficient, scalable shared infrastructure to support advancement of a diversified portfolio of cell therapy platforms across multiple cell types, including CAR-T, CAR-M, and CAR-NK.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 05/19/22 | $37,000,000 | Series A |
Kineticos Ventures | undisclosed |
